Evaluation of adjuvant treatment in stage II colorectal cancer.

Abstract

Introduction: 70 % of cases of colorectal cancer are diagnosed in stages in which surgical resection of the tumor is possible. However, 50% of these patients die or relapse due to metastatic disease. The aim of this study is to know the global and disease-free survival rate in patients with stage II colorectal cancer.

Methods: The present study is a descriptive, retrospective study conducted in the period from January 2006 to December 2010. Clinical-pathological characteristics of patients diagnosed with stage II colon adenocarcinoma who received adjuvant chemotherapy at the National Oncology Institute were analyzed. "Dr. Juan Tanca Marengo”, Solca-Guayaquil. Five-year survival is reported and compared to chi-square.

Results: 64 patients were included in the study. The global survival (SG) and disease free rate was 75 % at 5 years. 14 cases (21.9 %) presented tumor recurrence, with a survival 2.7 years. The patients who received the FOLFOX 4 protocol had a OS of 78.4 % at 5 years, while the patients who received FOLFOX 6 had a OS of 81.8 % at 5 years P = 0.57. The factors that significantly decrease survival were resection of 1-3 nodes survival 53.8 % P = 0.048, Recurrence survival 35.7 % P <0.0001. Age> 50 years survival 64.3 % P = 0.294, intestinal obstruction 67.6 % P = 0.193.

Conclusion: In this study the factors that influence the survival of patients with stage II colorectal cancer were inadequate lymph node resection, and recurrence of the disease. Global survival improves with the Folfox 6 protocol